Medical technology company Becton, Dickinson and Company (BD) has received an order from the Canadian Government for 7.6 million point-of-care, rapid SARS-CoV-2 antigen tests and 2,172 analysers.

Last month, the test has been authorised by Health Canada for use on the BD Veritor Plus System under Interim Order.

The BD Veritor Plus System is already in use in the country for the diagnosis of influenza A+B, respiratory syncytial virus (RSV), and group A strep.

The Government of Canada will use the tests to scale up the testing efforts to contain the spread of the Covid-19 in the country.

Canada Public Services and Procurement minister Anita Anand said: “The Government of Canada continues to work diligently to provide Canadians with access to effective and efficient Covid-19 testing solutions.

“This new agreement with BD is critical to assisting the provinces and territories in their respective efforts to reduce the spread of the virus. We will continue to support Canadians through the Covid-19 pandemic.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

BD’s SARS-CoV-2 antigen test is designed to offer results in approximately 15 minutes and uses a mid-nasal swab to collect patient samples. It is considered to be less invasive for the patient than nasopharyngeal sample collection.

The test reduces the burden on testing laboratories as it is performed at the point-of-care.

BD Canada president Greg Miziolek said: “As the demands for SARS-CoV-2 testing are increasing in Canada, we are excited to bring another testing solution to the Canadian market.

“The ability to perform SARS-CoV-2 testing at the point-of-care and deliver results while the patient waits will be truly impactful to help relieve some of the pressures on the testing labs and quickly identify affected patients. We applaud the federal government for their proactive approach in planning for future needs with a centralised order for antigen detection tests.”

BD has also been supporting SARS-CoV-2 molecular testing (RT-PCR) in Canadian labs on the BD MAX System.

Earlier this month, BD secured an order from the Dutch Ministry of Health for 9.2 million of its SARS-CoV-2 antigen tests for use on the BD Veritor Plus System.